In fact, since CD93 promotes the neovascularization of choriocapillaris in patients with AMD, the use of anti-CD93 drugs (e.g., monoclonal antibodies, non-coding RNA, rottlerin and Go6976), alone or in combination with anti-VEGF therapy, may significantly improve AMD treatment and outcome. This evidence concerns the gene VEGFA and age-related macular degeneration.